Nucleic acid approaches to antibody-based therapeutics for COVID-19: A perspective - 05/09/20

Key words : COVID-19, SARS-CoV-2, monoclonal antibody, nucleic acid, gene delivery
El texto completo de este artículo está disponible en PDF.
Esquema
Disclosure of potential conflict of interest: D. B. Weiner discloses the following paid associations with commercial partners: GeneOne (consultant), Geneos (Advisory Board), Astrazeneca (Advisory Board, speaker), Inovio (BOD, SRA, Stock), Pfizer (speaker), Merck (speaker), Sanofi (Advisory Board), and BBI (Advisory Board). E. Parzych declares no relevant conflicts of interest. |
Vol 146 - N° 3
P. 537-540 - septembre 2020 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.